Government of Telangana to facilitate strategic support and scale-up for the hub by encouraging more industries to join the consortium and benefit from it.
The Drugs Controller General of India (DCGI) approved the 2-deoxy-D-glucose (2-DG) drug for emergency use as an adjunct therapy in moderate to severe coronavirus patients in early May.
While Kotak Bank lost the most after shedding over 2 per cent, it was followed by Dr Reddy's, M&M, PowerGrid, NTPC, Nestle India and HDFC Bank.
Dr Reddy's, Bajaj Auto, Sun Pharma, Asian Paints, Maruti and NTPC were among the gainers, climbing up to 2.56 per cent.
DR Reddy’s Laboratories announced the commercial launch of 2-deoxy-D-glucose (2-DG) drug for Covid-19 on Monday.
Dr Reddy's has fully put in place cold storage logistics as well as track-and-trace arrangements for the vaccine.
Dr Reddy's Laboratories CEO Erez Israeli noted that it depends on the COVID-situation that how much the company would be able to put in during the fiscal.
Dr Reddy's which had received over two lakh vaccines from RDIF, recently soft-launched Sputnik V and tied up with Apollo Hospitals for piloting the vaccine.
1.5 lakh doses of Sputnik V arrives in India, likely to be incorporated in vaccination drive in few days
Dr Reddys has already received approval from Indian drug regulator for restricted emergency use of Sputnik V.